顺铂联合吉西他滨化疗用于紫杉烷/蒽环类耐药转移性乳腺癌

Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer.

作者信息

Somali Isil, Alacacioglu Ahmet, Tarhan Mustafa Oktay, Meydan Nezih, Erten Cigdem, Usalp Songul, Yilmaz Ugur

机构信息

Department of Medical Oncology, Ataturk Research and Training Hospital, Izmir, Turkey.

出版信息

Chemotherapy. 2009;55(3):155-60. doi: 10.1159/000214143. Epub 2009 Apr 22.

DOI:10.1159/000214143

PMID:19390188

Abstract

BACKGROUND

The most commonly used chemotherapeutic regimens in the treatment of metastatic breast cancer (MBC) include anthracyclines and taxanes. In our study, we investigated the efficacy and tolerability of cisplatin plus gemcitabine combination chemotherapy regimen in patients with MBC, who exhibited disease progression after anthracycline- and taxane-based chemotherapy.

METHODS

Thirty-three patients with taxane/anthracycline-resistant MBC have been treated with gemcitabine 1,000 mg/m(2) intravenously and cisplatin 30 mg/m(2) intravenously on days 1 and 8 of a 3-week treatment cycle.

RESULTS

Thirty-one patients were assessable for response. One of the 31 patients (3.2%) showed complete response, while 7 patients (22.6%) showed partial response; the objective response rate was 25.8%. Stable and progressive disease was observed in 6 (19.4%) and 17 patients (54.8%), respectively. The median time to progression was 4 months (95% CI 2.15-5.85). The median survival time of all patients was 9.5 months (95% CI 7.86-11.14).

CONCLUSION

Gemcitabine and cisplatin combination therapy is moderately active and safe in patients with MBC previously treated with anthracycline and taxanes.

摘要

背景

转移性乳腺癌（MBC）治疗中最常用的化疗方案包括蒽环类和紫杉烷类。在我们的研究中，我们调查了顺铂联合吉西他滨化疗方案对在接受基于蒽环类和紫杉烷类化疗后出现疾病进展的MBC患者的疗效和耐受性。

方法

33例对紫杉烷/蒽环类耐药的MBC患者在3周治疗周期的第1天和第8天接受静脉注射吉西他滨1000mg/m²和顺铂30mg/m²治疗。

结果

31例患者可评估疗效。31例患者中有1例（3.2%）显示完全缓解，7例（22.6%）显示部分缓解；客观缓解率为25.8%。分别有6例（19.4%）和17例患者（54.8%）观察到病情稳定和进展。中位疾病进展时间为4个月（95%CI 2.15 - 5.85）。所有患者的中位生存时间为9.5个月（95%CI 7.86 - 11.14）。